#USA #Malvern #Endo #ADRENALIN #Injectable Solutions

Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line

In an important development for healthcare providers, Endo, Inc. has announced the release of a new concentration of its ADRENALIN® product line—specifically, an 8 mg/250 mL premixed bag of epinephrine in 0.9% sodium chloride solution. This innovative offering is set to begin distribution during the week of May 19, 2025.

A Groundbreaking Addition to ADRENALIN®

Endo’s ADRENALIN® is not only the first FDA-approved but also the only commercially available manufacturer-prepared epinephrine premixed IV bag. This advancement intends to significantly enhance the efficiency and safety of patient care in hospital settings. According to Scott Sims, Senior Vice President and General Manager of Endo Injectable Solutions and Generics, the goal is to ease the burdens faced by hospital pharmacists and healthcare professionals, allowing them to prioritize patient care without the added complexities of preparing medications.

Key Benefits of the New Premixed Bag

The new ADRENALIN® premixed IV bag offers several advantageous features:

• - No Preparation Required: The premixed nature of the bag eliminates the need for compounding, thereby increasing efficiency.
• - Single-Port IV Tubing: Designed to minimize the risk of medication mixes, this feature increases safety during administration.
• - Extended Shelf Life: The product boasts a 24-month shelf life at room temperature, facilitating better inventory management in hospital pharmacies.

These features align with Endo’s commitment to streamlining operations within healthcare settings, supporting quality patient care, and reducing waste and costs associated with medication preparation.

Expansion of the ADRENALIN® Product Line

In addition to the newly launched 8 mg/250 mL bag, Endo also offers a 4 mg/250 mL version and is set to introduce additional concentrations, including 5 mg/250 mL and 10 mg/250 mL bags, alongside 1 mL single-dose and 30 mL multi-dose vials of epinephrine.

ADRENALIN® is prescribed for use in adult patients suffering from hypotension related to septic shock, proving to be a vital resource in critical medical situations.

Important Safety Information

While the launch marks a significant enhancement in epinephrine accessibility, it’s essential for healthcare providers to adhere to safety protocols. Due to varying individual responses to epinephrine, constant monitoring of blood pressure is necessary to prevent excessive increases. Patients on specific medications, such as monoamine oxidase inhibitors, may experience pronounced hypertensive effects, stressing the importance of tailored patient management.

Healthcare professionals must also remain vigilant regarding potential adverse reactions, which can include headaches, anxiety, and arrhythmias, among others. The risk of serious complications, such as pulmonary edema and tissue necrosis from intravenous infusion, necessitates ongoing training and awareness among administering personnel.

Moving Forward with Confidence

Endo’s innovations, such as the ADRENALIN® premixed IV bag, reaffirm the company's commitment to ensuring healthcare providers have access to effective and convenient treatment options. This aligns with their mission to improve the quality of life for all patients by continuously delivering essential medicines.

To learn more about Endo and its range of products, please visit their official website or follow their professional profiles on social media platforms.

For additional inquiries or detailed product information, healthcare practitioners may contact their representatives or visit Endo's informational site for comprehensive resources and guidelines.